Nasus Pharma, a clinical-stage pharmaceutical company, has had a transformative year in 2025. The company developed NS002, an intranasal epinephrine powder, showing potential for faster absorption in clinical trials. Nasus Pharma completed a successful IPO, raising $10 million. Collaborations with Aptar France S.A.S. and AptarGroup Inc. were expanded to support NS002’s development and commercialization. Health Canada approved a Phase 2 clinical study for NS002, with an interim analysis expected in early 2026. Nasus Pharma plans to reach key regulatory and clinical milestones in 2026. Their Nasax powder technology offers a needle-free, fast, and stable way to deliver life-saving medications.

Read more at GlobeNewswire: Nasus Pharma CEO Issues 2025 Letter to Shareholders